US-based biopharmaceutical firm Arrowhead has commenced its Phase II clinical trial of ARC-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency (AATD).

ARC-AAT is characterised by an unlocked nucleobase analog (UNA) containing RNAi trigger molecule for a systemic delivery using the Dynamic Polyconjugate delivery system.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It has proven its efficacy in affecting the Alpha-1 antitrypsin (AAT) gene transcript while decreasing the hepatic production of the mutant AAT (Z-AAT) protein in animal models.

The inflammatory Z-AAT protein is considered to be responsible for the cause of progressive liver disease in AATD patients.

"There remains no medical treatment for the liver disease associated with AATD, which is increasingly being recognised by patients and physicians as a serious problem."

The Phase II ARC-AAT trial has been designed as a multi-centre, open-label, multiple dose-escalation study of ARC-AAT and will include 12 participants.

It is intended to test the safety, efficacy and tolerability of multiple doses of ARC-AAT in treating AATD.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ARC-AAT will be administered in two dose levels and evaluated in two separate cohorts.

The subjects will receive a pre-dose biopsy, administered with seven doses of ARC-AAT and a post-dose biopsy after the 183rd day.

Arrowhead research and development CEO and head Bruce Given said: "There remains no medical treatment for the liver disease associated with AATD, which is increasingly being recognised by patients and physicians as a serious problem.

“Our Phase II 2001 study should give us, and the AATD community in general, the first insights into whether ARC-AAT can stop the progression of liver disease and possibly even allow the liver to recover and heal existing damage.

“This would be a significant breakthrough for patients."

The company is currently conducting a Phase I clinical trial of ARC-AAT with Part A involving healthy volunteers and Part B involving AATD patients.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact